Cargando…
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is the second most frequent liver cancer. The overall survival of iCCA and other biliary tract cancers (BTC) remains poor. Recently, the ABC‐06 trial reported the superiority of FOLFOX vs clinical observation as a second‐line treatment. Still, the s...
Autores principales: | Tovoli, Francesco, Garajová, Ingrid, Gelsomino, Fabio, Iavarone, Massimo, Federico, Piera, Salati, Massimiliano, Corianò, Matilde, Caputo, Francesco, De Lorenzo, Stefania, Granito, Alessandro, Renzulli, Matteo, Daniele, Bruno, Piscaglia, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300150/ https://www.ncbi.nlm.nih.gov/pubmed/34826193 http://dx.doi.org/10.1111/liv.15117 |
Ejemplares similares
-
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
por: Garajová, Ingrid, et al.
Publicado: (2023) -
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
por: Garajová, Ingrid, et al.
Publicado: (2023) -
DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01
por: Jarman, Edward J., et al.
Publicado: (2022) -
Should patients on levothyroxine therapy be screened for pancreatic cancer?
por: Garajová, Ingrid, et al.
Publicado: (2022) -
Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)